Radiopharm Theranostics (RADX) Non-Current Assets (2024 - 2025)
Radiopharm Theranostics (RADX) reported Non-Current Assets of $298620.5 for Q2 2025, down 7.88% year-over-year from $324161.5 in Q2 2024, and down 7.88% quarter-over-quarter from $324161.5 in Q2 2024.
Radiopharm Theranostics (RADX) Non-Current Assets (2024 - 2025) Analysis & Trends
Radiopharm Theranostics (RADX) has 2 years of Non-Current Assets data on file, last reported at $298620.5 in Q2 2025.
- Non-Current Assets for Q2 2025 came in at $298620.5, down 7.88% year-over-year; the trailing twelve-month figure through Jun 2025 was $298620.5 (down 7.88% YoY), and the FY2025 annual result was $46.6 million, down 5.2% from the prior year.
- Non-Current Assets declined to $298620.5 in Q2 2025 per RADX's latest filing, from $324161.5 in the prior quarter.
- Over five years, Non-Current Assets peaked at $324161.5 in Q2 2024 and troughed at $298620.5 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 62,953.78 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 486.60 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 30.30 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 5.18 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 14.75 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 39.71 Mn |
| 10 | Radiopharm Theranostics | 5.82 Bn | 5.81 Bn | - | 298,620.48 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 298,620.48 |
| Jun 30, 2024 | 324,161.52 |